SCHEMBL17257663

SCHEMBL17257663

C/C(=N\OS(=O)(=O)c1ccccc1)c1sccc1C#N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTDSP1 Q9GZU7 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPT P10636 5/20 0.39
ALDH1A1 P00352 7/20 0.38
KMT2A Q03164 4/20 0.38
KDM4E B2RXH2 3/20 0.38
NPSR1 Q6W5P4 6/20 0.37
MEN1 O00255 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HPGD P15428 1/20 0.36
BLM P54132 1/20 0.36
MAPK1 P28482 2/20 0.35
XBP1 P17861 4/20 0.35
MPI P34949 4/20 0.35
HSP90AA1 P07900 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
LMNA P02545 4/20 0.34
RAB9A P51151 3/20 0.34
POLB P06746 1/20 0.34
S1PR2 O95136 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17257664 1.00 CTDSP1 (0.39) CTDSP1L3MBTL1MAPTALDH1A1KMT2A
SCHEMBL17257278 0.80 MAPT (0.41) MAPTALDH1A1KMT2AKDM4ENPSR1
SCHEMBL17257276 0.80 MAPT (0.41) MAPTALDH1A1KMT2AKDM4ENPSR1
SCHEMBL17257207 0.75 ALDH1A1 (0.47) MAPTALDH1A1KMT2AKDM4ENPSR1
SCHEMBL17257483 0.75 MAPK1 (0.39) L3MBTL1MAPTALDH1A1KMT2AKDM4E
SCHEMBL17257209 0.75 ALDH1A1 (0.47) MAPTALDH1A1KMT2AKDM4ENPSR1
SCHEMBL17257482 0.75 MAPK1 (0.39) L3MBTL1MAPTALDH1A1KMT2AKDM4E
SCHEMBL17256847 0.75 NPC1 (0.52) L3MBTL1MAPTALDH1A1KMT2AKDM4E
SCHEMBL17256844 0.75 NPC1 (0.52) L3MBTL1MAPTALDH1A1KMT2AKDM4E
SCHEMBL17256806 0.74 POLB (0.38) L3MBTL1MAPTALDH1A1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group BRIDGESTONE CORPORATION (JP) 2018-07-24 US claimed
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORPORATION (JP) 2015-11-19 US claimed
EP-3143055-B1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORP (JP) 2019-09-04 EP disclosed
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group BRIDGESTONE CORPORATION (JP) 2018-07-24 US disclosed
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORPORATION (JP) 2015-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group PAM, PPOX, MB CTDSP1 209/4885L3MBTL1 4364/4885MAPT 2157/4885
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP PAM, PPOX, MB CTDSP1 209/4885L3MBTL1 4364/4885MAPT 2157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.